Anavex Life Sciences Corp. announced that it has withdrawn its application for marketing authorization of its lead Alzheimer’s candidate blarcamesine in the European Union, following a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The decision comes after a negative trend vote in December 2025 and a formal refusal of the application.
The CHMP’s refusal was based on a review of the clinical data that found the evidence insufficient to demonstrate the drug’s effectiveness and safety, particularly in patients without a SIGMAR1 gene mutation. Methodological concerns were cited, including issues with data integrity and statistical analysis, while safety data highlighted a high incidence of treatment‑related dizziness, confusion, and unresolved impurity concerns.
In light of the CHMP feedback, Anavex will review the comments, collect additional data, and conduct further analyses before deciding on future regulatory steps. The company remains engaged with the U.S. Food and Drug Administration, where it was invited in January 2026 to present its Alzheimer’s trial results and plans to submit the Phase IIb/III data set for a potential New Drug Application.
Financially, Anavex reported a net loss of $9.8 million for Q4 2025 and held $102.6 million in cash and equivalents as of September 30 2025, giving the company a runway of more than three years to fund ongoing research and development activities.
Investors reacted negatively to the withdrawal, reflecting concerns about the company’s ability to secure regulatory approval in a major market and the potential impact on future revenue streams.
Management reiterated its commitment to advancing blarcamesine, noting that the company will continue to pursue clinical development and explore additional indications, including Parkinson’s disease dementia and Rett syndrome, while also progressing its other candidate ANAVEX®3‑71 for schizophrenia.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.